5-Hydroxytryptamine receptor antagonists as antihypertensive drugs

  • Pramod R. Saxena
Part of the Developments in CardioCardiovascular Pharmacology of 5-Hydroxytryptamine book series (DICM, volume 106)


Though 5-hydroxytryptamine (5-HT) exerts powerful pharmacological effects on the heart and blood vessels [1, 2], the physiological role of 5-HT in cardiovascular regulation is not clear. The effect of 5-HT on arterial blood pressure is triphasic [3] and consists mainly of an initial short-lasting depressor phase due to the Von Bezold-Jarisch reflex mediated by 5-HT3 receptors [4–7], followed by a 5-HT2 receptor-mediated hypertensive phase [5, 6, 8], and a late, long-lasting, hypotensive phase mediated by 5-HT1like receptor stimulation [see 9]. It is, therefore, obvious that only antagonists at 5-HT2 receptors may be expected to have an antihypertensive effect in the event that these receptors are involved in the pathophysiology of hypertension.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Saxena PR (1986): Nature of the 5-hydroxytryptamine receptors in mammalian heart. Prog Pharmacol 6: 173–185.Google Scholar
  2. 2.
    Cohen ML (1989): Receptors for 5-hydroxytryptamine in the cardiovascular system. Ch. XXII, This book.Google Scholar
  3. 3.
    Page IH (1957): Cardiovascular actions of serotonin (5-hydroxytryptamine), pp. 93–108 in: Lewis GP (ed), 5-Hydroxytryptamine. London: Pergamon Press.Google Scholar
  4. 4.
    Fozard JR (1984): MDL 72222: a potent and highly selective antagonist at neuronal 5-HT receptors. Naunyn Schmiedebergs Arch Pharmacol 326: 36–44.PubMedCrossRefGoogle Scholar
  5. 5.
    Kalkman HO, Engel G, Hoyer D (1984): Three distinct types of serotonergic receptors mediate the triphasic blood pressure response to serotonin in rats. J Hypertens 6 (suppl. 2): S421–S428.Google Scholar
  6. 6.
    Saxena PR, Lawang A (1985): A comparison of cardiovascular and smooth muscle effects of 5-hydroxytryptamine and 5-carboxamidotryptamine, a selective agonist of 5-HT1-like receptors. Arc Int Pharmacodyn Ther 227: 235–252.Google Scholar
  7. 7.
    Saxena PR, Mylecharane EJ, Heiligers J (1985): Analysis of the heart rate effects of 5-hydroxytryptamine in the cat; mediation by 5-HT1-like receptors. Naunyn Schmiedebergs Arch Pharmacol 330: 121–129.PubMedCrossRefGoogle Scholar
  8. 8.
    Leysen JE, De Chaffoy De Courcelles D, De Clerck F, Niemegeers CJE, Van Nueten JM (1984): Serotonin-S2 receptor binding sites and functional correlates. Neuropharmacology 23: 1493–1501.Google Scholar
  9. 9.
    Saxena PR, Bolt GR, Dhasmana KM (1987): Serotonin agonists and antagonists in experimental hypertension. J Cardiovasc Pharmacol 10 (suppl. 3): S12–S18.CrossRefGoogle Scholar
  10. 10.
    Bolt GR, Saxena PR (1985): Cardiovascular profile and hypotensive mechanism of ketanserin in the rabbit. Hypertension 7: 499–506.PubMedCrossRefGoogle Scholar
  11. 11.
    Vanhoutte PM, Ball SG, Berdeaux A, Cohen ML, Hedner T, McCall R, Ramage AG, Reimann IH, Richer C, Saxena PR, Schalekamp MADH, Struyker-Boudier HAJ, Symoens J, Van Nueten JM, Van Zwieten PA (1986): Mechanism of action of ketanserin in hypertension. Trends Pharmacol Sci 7: 58–59.CrossRefGoogle Scholar
  12. 12.
    Vanhoutte PM, Amery A, Birkenhäger W, Breckenridge A, Bühler F, Distler A, Dormandy J, Doyle A, Frohlich E, Hansson L, Hedner T, Hollenberg N, Jensen H-E, Lund-Johansen P, Meyer P, Opie L, Robertson I, Safar M, Schalekamp M, Symoens J, Trap-Jensen J, Zanchetti A (1988): Serotonergic mechanisms in hypertension: Focus on the effects of ketanserin. Hypertension 11: 111–133.PubMedCrossRefGoogle Scholar
  13. 13.
    Van Nueten JM, Schuurkes JAJ, De Ridder WJE, Kuyps JJMD, Janssens WJ (1986): Comparative pharmacological profile of ritanserin and ketanserin. Drug Dev Res 8: 187–195.CrossRefGoogle Scholar
  14. 14.
    Van Nueten JM, Xhonneux R, Janssens WJ, Schuurkes JAJ, Janssen PAJ (1988): Interaction between S2-serotonergic and alpha1-adrenergic receptors and control of blood pressure, (in press) in: Vanhoutte PM (ed), Mechanism of Vasodilatation. New York: Raven Press.Google Scholar
  15. 15.
    Blauw GJ, van Brummelen P, Chang PC, Van Zwieten PA (1988): Regional vascular effects of serotonin and ketanserin in young, healthy subjects. Hypertension 11: 256–263.PubMedCrossRefGoogle Scholar
  16. 16.
    Wenting GJ, Manin’t Veld AJ, Woittiez AJJ, Boomsma F, Schalekamp MADH (1982): Haemodynamic effects of ketanserin, a selective 5-hydroxytryptamine (serotonin) receptor antagonist, in essential hypertension. Clin Sci 63:435S–438S.Google Scholar
  17. 17.
    Janssen PAJ (1985): Pharmacology of potent and selective S2-serotonergic antagonists. J Cardiovasc Pharmacol 1 (suppl. 7): S2–S11.CrossRefGoogle Scholar
  18. 18.
    Symoens J, Vanhoutte PM (1985): The role of serotonin in blood pressure regulation, pp. 141–164 in: Smith JAR, Watkins J (eds), Care of the postoperative patient. London: Butterworth.Google Scholar
  19. 19.
    Cohen ML, Fuller RW, Kurz KD (1983): LY 53857, a selective new potent serotonergic (5-HT2) receptor antagonist, does not lower blood pressure in the spontaneously hypertensive rat. J Pharmacol Exp Ther 221 : 327–332.Google Scholar
  20. 20.
    Kalkman HO, Harms YM, Van Gelderen EM, Batink HD, Timmermans PBMWM, Van Zwieten PA (1983) Hypotensive activity of serotonin antagonists; correlation with α1-adrenoceptor and serotonin receptor blockade. Life Sci 32: 1499–1505.PubMedCrossRefGoogle Scholar
  21. 21.
    Hosie J, Stott DJ, Robertson JIS, Ball SG (1987): Does acute serotenergic type-2 antagonism reduce blood pressure? Comparative effects of single doses of ritanserin and ketanserin in essential hypertension. J Cardiovasc Pharmacol 10 (suppl. 3): S86–S88.CrossRefGoogle Scholar
  22. 22.
    Van Zwieten PA, Mathy MJ, Boddeke HWGM, Doods HN (1987): Central hypotensive activity of ketanserin in cats. J Cardiovasc Pharmacol 10 (suppl 3): S54–S58.CrossRefGoogle Scholar
  23. 23.
    Blackburn TP, Haworth SJ, Jessup CL, Morton PB, Williams C (1989): ICI 170809, A selective 5-hydroxytryptamine antagonist, inhibits human platelet aggregation in vitro and exvivo. Ch. XXXX, This book.Google Scholar
  24. 24.
    Fozard JR (1982): Mechanism of the hypotensive effect of ketanserin. J Cardiovasc Pharmacol 4: 829–838.PubMedCrossRefGoogle Scholar
  25. 25.
    Kalkman HO, Timmermans PBMWM, Van Zwieten PA (1982): Characterization of the antihypertensive properties of ketanserin (R41468) in rats. J Pharmacol Exp Ther 222: 227–231.PubMedGoogle Scholar
  26. 26.
    Wright CE, Angus JA (1983): Haemodynamic response to ketanserin in rabbits with page hypertension: Comparison with prazosin J Hypertension 1: 183–190.CrossRefGoogle Scholar
  27. 27.
    Reimann IW, Frohlich JC (1983): Mechanism of antihypertensive action of ketanserin in man. Br Med J 287: 381–383.CrossRefGoogle Scholar
  28. 28.
    Fagard R, Fioli R, Lijnen P, Staessen J, Moeman E, De Schaepdryver A, Amery A (1984): Haemodynamic and humoral responses to chronic ketanserin treatment in essential hypertension. Br Heart J 51: 149–156.PubMedCentralPubMedCrossRefGoogle Scholar
  29. 29.
    Casiglia E, Gava R, Semplicini A, Nicolin P, Pessina AC (1986): The mechanism of the antihypertensive effects of ketanserin: a comparison with metoprolol. Br J Clin Pharmacol 22: 751–752.PubMedCentralPubMedCrossRefGoogle Scholar
  30. 30.
    Berdeaux A, Edouard A, Samii K, Giudicelli JF (1987): Ketanserin and the arterial baroreceptor reflex in normotensive subjects. Eur J Clin Pharmacol 32: 27–33.PubMedCrossRefGoogle Scholar
  31. 31.
    Wenting GJ, Woittiez AJJ, Manin’t Veld AJ, Schalekamp MADH (1984): 5-HT, alpha- adrenoceptors, and blood pressure; effects of ketanserin in essential hypertension and autonomic insufficiency. Hypertension 6:100–109.PubMedCrossRefGoogle Scholar
  32. 32.
    Dragsted N, Boeck V (1988): Cardiovascular effects of irindalone, a novel 5-HT2 antagonist with antihypertensive activity (Abstr P43). International Congress on Cardiovascular Pharmacology of 5-HT, Oct 4–7, Amsterdam.Google Scholar
  33. 33.
    Schröder G, Beckmann R, Müller B, Schulz BG, Stock G (1988): Pharmacological profile of ZK 33.839, a new 5-HT2/a1 -antagonist (Abstr P38). International Congress on Cardiovascular Pharmacology of 5-HT, Oct 4–7, Amsterdam.Google Scholar
  34. 34.
    Van der Starre PJA (1988): Ketanserin and hypertension in cardiac surgery. Thesis, State University of Limburg, Maastricht, The Netherlands.Google Scholar
  35. 35.
    Herrmann WM, Baumgartner P (1986): Combined pharmaco-EEG and pharmacopsy- chological study to estimate CNS effects of ketanserin in hypertensive patients. Neuropsychobiology 16: 47–56.PubMedCrossRefGoogle Scholar
  36. 36.
    McCall RB, Schuette MR (1984): Evidence for an alpha-1 receptor-mediated central sympathoinhibitory action of ketanserin. J Pharmacol Exp Ther 228: 704–710.PubMedGoogle Scholar
  37. 37.
    Ramage AG (1985): The effects of ketanserin, methysergide and LY 53857 on sympathetic nerve activity. Eur J Pharmacol 113: 295–303.PubMedCrossRefGoogle Scholar
  38. 38.
    Hedner T, Pettersson A, Gradin K, Persson B (1986): Peripheral serotonergic mecha- nsims in cardiovascular regulation in the spontaneously hypertensive rat. J Hypertension 4 (suppl. 3): S223–S225.Google Scholar
  39. 39.
    Copeland IW, Bentley GA (1985): A possible central action of prazosin and ketanserin to cause hypotension. J Cardiovasc Pharmacol 7: 822–825.PubMedCrossRefGoogle Scholar
  40. 40.
    Dhasmana KM, Banerjee AK, Saxena PR (1989): The effects of intrathecal ketanserin and phentolamine on heart rate and arterial blood pressure in the rat. Ch. XXX, This book.Google Scholar
  41. 41.
    Phillips CA, Mylecharane EJ, Markus JK, Shaw J (1985): Hypotensive actions of ketanserin in dogs: involvement of a centrally mediated inhibition of sympathetic vascular tone. Eur J Pharmacol 111: 319–327.PubMedCrossRefGoogle Scholar
  42. 42.
    Woittiez AJJ, Wenting GJ, Van der Meiracker AH, Ritsma Van Eck HJ, Manin’t Veld AJ, Zantvoort FA, Schalekamp MADH (1986): Chronic effect of ketanserin in mild to moderate essential hypertension. Hypertension 8: 167–173.Google Scholar
  43. 43.
    Bradley PB, Engel G, Feniuk W, Fozard JR, Humphrey PPA, Middlemiss DN, Mylecharane EJ, Richardson B, Saxena PR (1986): Proposals for the classification and nomenclature of functional receptors for 5-hydroxytryptamine. Neuropharmacology 25: 563–575.PubMedCrossRefGoogle Scholar
  44. 44.
    Antonaccio MJ, Taylor DJ (1977): Reduction in blood pressure, sympathetic nerve discharge and centrally evoked pressor responses by methysergide in anaesthetized cats. Eur J Pharmacol 42: 331–338.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 1990

Authors and Affiliations

  • Pramod R. Saxena

There are no affiliations available

Personalised recommendations